Short-term administration of a small thyroxine dose to euthyroid type 2 diabetic patients improves the fasting lipoprotein profile#

Q Medicine

Clinical Lipidology Pub Date : 2017-01-01 DOI:10.1080/17584299.2016.1268316

F. Spanoudi, E. Vassilatou, E. Maratou, P. Mitrou, E. Hatziagelaki, N. Papanas, G. Dimitriadis, V. Lambadiari

{"title":"Short-term administration of a small thyroxine dose to euthyroid type 2 diabetic patients improves the fasting lipoprotein profile#","authors":"F. Spanoudi, E. Vassilatou, E. Maratou, P. Mitrou, E. Hatziagelaki, N. Papanas, G. Dimitriadis, V. Lambadiari","doi":"10.1080/17584299.2016.1268316","DOIUrl":null,"url":null,"abstract":"ABSTRACT Background: Although several studies have assessed the association between thyroid hormones and dyslipidaemia, whether influencing thyroid function improves the lipid profile in euthyroid diabetic patients has not been studied. Methods: Fasting lipids were assessed in 11 euthyroid, treatment naive patients with type 2 diabetes (T2DM) and a micronodular texture of the thyroid gland (age: 43 ± 3.8 years, body mass index (BMI) 27.5 ± 1.4 kg/m2, triiodothyronine (T3) 119 ± 5.7 ng/dl, thyroxine (T4) 8.13 ± 0.46 μg/dl, thyroid- stimulating hormone (TSH) 1.51 ± 0.14 μIU/ml, free thyroxine (FT4) 1.272 ± 0.047 ng/dl) before and after administration of 50 μg of T4 once daily for 2 months. A placebo was given to 11 age, sex and BMI-matched euthyroid, treatment naive patients with T2DM. Care was taken to avoid even subclinical hyperthyroidism. Results: TSH fell significantly post-treatment (1.51 ± 0.11 vs. 0.79 ± 0.11 μIU/ml, p < 0.0001), but remained within the reference range. Total cholesterol (212 ± 21 vs. 158 ± 10 mg/dl, p = 0.003), low-density lipoprotein cholesterol (146 ± 17 vs. 112 ± 9 mg/dl, p = 0.007), high density lipoprotein cholesterol (51 ± 4 vs. 40 ± 3 mg/dl p = 0.001), triglycerides (93 ± 13 vs. 72 ± 8 mg/dl, p = 0.015), apolipoprotein A1 (167 ± 15 vs. 127 ± 8 mg/dl, p = 0.004), apolipoprotein B (101 ± 13 vs. 72 ± 7 mg/dl, p = 0.009) and lipoprotein (a) (60 ± 15 vs. 41 ± 11 mg/dl p = 0.009) all fell significantly after T4 administration for 2 months. No changes were observed in the placebo group. Conclusions: Small doses of T4 administered to euthyroid patients with T2DM significantly improved lipid levels. This could contribute to a reduced risk of macrovascular complications.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"101 1","pages":"1 - 6"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17584299.2016.1268316","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 3

Abstract

ABSTRACT Background: Although several studies have assessed the association between thyroid hormones and dyslipidaemia, whether influencing thyroid function improves the lipid profile in euthyroid diabetic patients has not been studied. Methods: Fasting lipids were assessed in 11 euthyroid, treatment naive patients with type 2 diabetes (T2DM) and a micronodular texture of the thyroid gland (age: 43 ± 3.8 years, body mass index (BMI) 27.5 ± 1.4 kg/m2, triiodothyronine (T3) 119 ± 5.7 ng/dl, thyroxine (T4) 8.13 ± 0.46 μg/dl, thyroid- stimulating hormone (TSH) 1.51 ± 0.14 μIU/ml, free thyroxine (FT4) 1.272 ± 0.047 ng/dl) before and after administration of 50 μg of T4 once daily for 2 months. A placebo was given to 11 age, sex and BMI-matched euthyroid, treatment naive patients with T2DM. Care was taken to avoid even subclinical hyperthyroidism. Results: TSH fell significantly post-treatment (1.51 ± 0.11 vs. 0.79 ± 0.11 μIU/ml, p < 0.0001), but remained within the reference range. Total cholesterol (212 ± 21 vs. 158 ± 10 mg/dl, p = 0.003), low-density lipoprotein cholesterol (146 ± 17 vs. 112 ± 9 mg/dl, p = 0.007), high density lipoprotein cholesterol (51 ± 4 vs. 40 ± 3 mg/dl p = 0.001), triglycerides (93 ± 13 vs. 72 ± 8 mg/dl, p = 0.015), apolipoprotein A1 (167 ± 15 vs. 127 ± 8 mg/dl, p = 0.004), apolipoprotein B (101 ± 13 vs. 72 ± 7 mg/dl, p = 0.009) and lipoprotein (a) (60 ± 15 vs. 41 ± 11 mg/dl p = 0.009) all fell significantly after T4 administration for 2 months. No changes were observed in the placebo group. Conclusions: Small doses of T4 administered to euthyroid patients with T2DM significantly improved lipid levels. This could contribute to a reduced risk of macrovascular complications.

查看原文本刊更多论文

甲状腺功能良好的2型糖尿病患者短期服用小剂量甲状腺素可改善空腹脂蛋白谱#

背景:虽然有几项研究评估了甲状腺激素与血脂异常血症之间的关系，但影响甲状腺功能是否能改善甲状腺功能正常的糖尿病患者的血脂状况尚未得到研究。方法:禁食脂肪在11 euthyroid评估,天真的患者治疗2型糖尿病(T2DM)病人体内和甲状腺结节性结构(年龄:43±3.8年,身体质量指数(BMI) 27.5±1.4 kg / m2,三碘甲状腺氨酸(T3) 119±5.7毫微克/分升,甲状腺素(T4) 8.13±0.46μg / dl -刺激甲状腺激素(TSH) 1.51±0.14μ国际单位/毫升,游离甲状腺素(FT4) 1.272±0.047 ng / dl)之前和之后政府50μg的T4每天2个月一次。给11名年龄、性别和bmi匹配的甲状腺功能正常的T2DM患者服用安慰剂。注意甚至避免亚临床甲状腺功能亢进。结果:治疗后TSH显著下降(1.51±0.11 vs. 0.79±0.11 μIU/ml, p < 0.0001)，但仍在参考范围内。总胆固醇(212±21比158±10 mg / dl, p = 0.003),低密度脂蛋白胆固醇(146±17和112±9 mg / dl, p = 0.007),高密度脂蛋白胆固醇(51±4和40±3 mg / dl p = 0.001),甘油三酯(93±13和72±8 mg / dl, p = 0.015),载脂蛋白A1(167±15和127±8 mg / dl, p = 0.004),载脂蛋白B(101±13和72±7 mg / dl, p = 0.009)和脂蛋白(a)(60±15和41±11 mg / dl p = 0.009)所有T4管理2个月后下降明显。安慰剂组没有观察到任何变化。结论:小剂量T4给予甲状腺功能正常的T2DM患者可显著改善血脂水平。这可能有助于降低大血管并发症的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.